Systematic review of the cost-effectiveness of influenza immunization programs

Vaccine

Volumn 35, Issue 15, 2017, Pages 1828-1843

  Ting, Eon E K ^a,b,c   Sander, Beate ^a,d   Ungar, Wendy J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ASTRAZENECA   (United Kingdom)

^d PUBLIC HEALTH ONTARIO   (Canada)

Author keywords

Adults; Children; Cost effectiveness; High risk; Influenza immunization; Pregnant women

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; CHILD; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE SYSTEM; HIGH RISK POPULATION; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VACCINATION; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; PUERPERIUM; QUALITY ADJUSTED LIFE YEAR; REVIEW; SOCIAL ASPECT; SYSTEMATIC REVIEW; VACCINE PRODUCTION; WORLD HEALTH ORGANIZATION; CANADA; COST BENEFIT ANALYSIS; ECONOMICS; PREVENTIVE HEALTH SERVICE;

CANADA; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA, HUMAN;

EID: 85015668837     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.02.044     Document Type: Review

References (61)

1. [1] Public Health Agency of Canada: National Advisory Committee on Immunization. Statement on Seasonal Influenza Vaccine for 2014–2015. Ottawa; 2014.
2. [2] Schanzer, D.L., Sevenhuysen, C., Winchester, B., Mersereau, T., Estimating Influenza Deaths in Canada, 1992–2009. PLoS ONE, 8, 2013, e80481, 10.1371/journal.pone.0080481.
3. [3] Molinari N-AM, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086–96. http://dx.doi.org/10.1016/j.vaccine.2007.03.046.
4. [4] Canadian Agency for Drugs and Technologies in Health. Grey Matters: a practical tool for searching health-related grey literature | CADTH.ca 2014. https://www.cadth.ca/resources/finding-evidence/grey-matters [accessed September 17, 2016].
5. [5] Scottish Intercollegiate Guidelines Network. Critical appraisal: notes and checklists; 2015. < http://www.sign.ac.uk/methodology/checklists.html> [accessed September 17, 2016].
6. [6] Initiative for Vaccine Research. WHO guide for standardization of economic evaluations of immunization programmes; 2008.
7. [7] Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies; 2006.
8. [8] Marchetti, M., Kühnel, U.M., Colombo, G.L., Esposito, S., Principi, N., Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Hum Vaccin 3 (2007), 14–22, 10.4161/hv.3.1.3657.
9. [9] Pitman, R.J., Nagy, L.D., Sculpher, M.J., Cost-effectiveness of childhood influenza vaccination in England and Wales: results from a dynamic transmission model. Vaccine 31 (2013), 927–942, 10.1016/j.vaccine.2012.12.010.
10. [10] Nichol, K.L., Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 161 (2001), 749–759 doi:ioi00322 [pii].
11. [11] Nichol, K.L., Mallon, K.P., Mendelman, P.M., Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 21 (2003), 2216–2226, 10.1016/S0264-410X(03)00029-X.
12. [12] Turner, D.A., Wailoo, A.J., Cooper, N.J., Sutton, A.J., Abrams, K.R., Nicholson, K.G., The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of age. Vaccine 24 (2006), 1035–1043, 10.1016/j.vaccine.2004.12.033.
13. [13] Clements, K.M., Chancellor, J., Nichol, K., Delong, K., Thompson, D., Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Heal 14 (2011), 800–811, 10.1016/j.jval.2011.03.005.
14. [14] Prosser, L.A., Bridges, C.B., Uyeki, T.M., Hinrichsen, V.L., Meltzer, M.I., Molinari, N.A.M., et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 12 (2006), 1548–1558, 10.3201/eid1210.051015.
15. [15] Schmier J, Li S, King JC, Nichol K, Mahadevia PJ. Market watch: Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial. Health Aff 2008;27. http://dx.doi.org/10.1377/hlthaff.27.2.w96.
16. [16] Salo, H., Kilpi, T., Sintonen, H., Linna, M., Peltola, V., Heikkinen, T., Cost-effectiveness of influenza vaccination of healthy children. Vaccine 24 (2006), 4934–4941, 10.1016/j.vaccine.2006.03.057.
17. [17] Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, Raboud JM, et al. Economic appraisal of Ontario's universal influenza immunization program: a cost-utility analysis. PLoS Med 2010;7. http://dx.doi.org/10.1371/journal.pmed.1000256.
18. [18] Bridges, C.B., Thompson, W.W., Meltzer, M.I., Reeve, G.R., Talamonti, W.J., Cox, N.J., et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 284 (2000), 1655–1663, 10.1001/jama.284.13.1655.
19. [19] Esposito, S., Marchisio, P., Bosis, S., Lambertini, L., Claut, L., Faelli, N., et al. Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine 24 (2006), 629–635, 10.1016/j.vaccine.2005.08.054.
20. [20] Teufel, R.J., Basco, W.T., Simpson, K.N., Cost effectiveness of an inpatient influenza immunization assessment and delivery program for children with asthma. J Hosp Med 3 (2008), 134–141, 10.1002/jhm.286.
21. [21] Kumpulainen, V., Mäkelä, M., Influenza vaccination among healthy employees: a cost-benefit analysis. Scand J Infect Dis 29 (1997), 181–185.
22. [22] Campbell, D.S., Rumley, M.H., Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med 39 (1997), 408–414, 10.1097/00043764-199705000-00006.
23. [23] Cicchetti, A., Ruggeri, M., Gitto, L., Mennini, F.S., Extending influenza vaccination to individuals aged 50–64: a budget impact analysis. Int J Technol Assess Health Care 26 (2010), 288–293, 10.1017/S0266462310000280.
24. [24] Meltzer, M.I., Neuzil, K.M., Griffin, M.R., Fukuda, K., An economic analysis of annual influenza vaccination of children. Vaccine 23 (2005), 1004–1014, 10.1016/j.vaccine.2004.07.040.
25. [25] Parlevliet, W., De Borgie, C., Frijstein, G., Guchelaar, H.J., Cost-benefit analysis of vaccination against influenza of employees from an Academic Medical Centre. Dis Manag Heal Outcomes 10:9 (2002), 579–587.
26. [26] Maciosek, M.V., Solberg, L.I., Coffield, A.B., Edwards, N.M., Goodman, M.J., Influenza vaccination. Health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Am J Prev Med 31 (2006), 72–79, 10.1016/j.amepre.2006.03.008.
27. [27] Yoo, B.K., Humiston, S.G., Szilagyi, P.G., Schaffer, S.J., Long, C., Kolasa, M., Cost effectiveness analysis of elementary school-located vaccination against influenza – results from a randomized controlled trial. Vaccine 31 (2013), 2156–2164, 10.1016/j.vaccine.2013.02.052.
28. [28] Aballéa, S., De Juanes, J.R., Barbieri, M., Martin, M., Chancellor, J., Oyagüez, I., et al. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain. Vaccine 25 (2007), 6900–6910, 10.1016/j.vaccine.2007.07.033.
29. [29] Newall, A.T., Scuffham, P.A., Kelly, H., Harsley, S., MacIntyre, C.R., The cost-effectiveness of a universal influenza vaccination program for adults aged 50–64 years in Australia. Vaccine 26 (2008), 2142–2153, 10.1016/j.vaccine.2008.01.050.
30. [30] Nichol KL, Goodman M. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years. Vaccine 2002;20:0–3. http://dx.doi.org/10.1016/S0264-410X(02)00124-X.
31. [31] Beigi, R.H., Wiringa, A.E., Bailey, R.R., Assi, T.-M., Lee, B.Y., Economic value of seasonal and pandemic influenza vaccination during pregnancy. Clin Infect Dis 49 (2009), 1784–1792, 10.1086/649013.
32. [32] Aballéa, S., Chancellor, J., Martin, M., Wutzler, P., Carrat, F., Gasparini, R., et al. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Heal 10 (2007), 98–116, 10.1111/j.1524-4733.2006.00157.x.
33. [33] Salleras, L., Navas, E., Domínguez, A., Ibáñez, D., Prat, A., Garrido, P., et al. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3–14 years during the annual health examination in private paediatric offices. Vaccine 27 (2009), 3454–3458, 10.1016/j.vaccine.2009.01.053.
34. [34] Avritscher, E.B.C., Cooksley, C.D., Geraci, J.M., Bekele, B.N., Cantor, S.B., Rolston, K.V., et al. Cost-effectiveness of influenza vaccination in working-age cancer patients. Cancer 109 (2007), 2357–2364, 10.1002/cncr.22670.
35. [35] Skedgel, C., Langley, J.M., MacDonald, N.E., Scott, J., McNeil, S., An incremental economic evaluation of targeted and universal influenza vaccination in pregnant women. Can J Public Heal 102 (2011), 445–450.
36. [36] Ding, Y., Zangwill, K.M., Hay, J.W., Allred, N.J., Yeh, S.H., Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol 119 (2012), 306–314, 10.1097/AOG.0b013e318242af27.
37. [37] Roberts, S., Hollier, L.M., Sheffield, J., Laibl, V., Wendel, G.D., Cost-effectiveness of universal influenza vaccination in a pregnant population. Obstet Gynecol 107 (2006), 1323–1329, 10.1097/01.AOG.0000210225.45986.99.
38. [38] Jit, M., Cromer, D., Baguelin, M., Stowe, J., Andrews, N., Miller, E., The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine 29 (2010), 115–122, 10.1016/j.vaccine.2010.08.078.
39. [39] Blommaert, A., Bilcke, J., Vandendijck, Y., Hanquet, G., Hens, N., Beutels, P., Cost-effectiveness of seasonal influenza vaccination in pregnant women, health care workers and persons with underlying illnesses in Belgium. Vaccine 32 (2014), 6075–6083, 10.1016/j.vaccine.2014.08.085.
40. [40] Cohen, G.M., Nettleman, M.D., Economic impact of influenza vaccination in preschool children. Pediatrics 106 (2010), 973–976.
41. [41] Luce, B.R., Zangwill, K.M., Palmer, C.S., Mendelman, P.M., Yan, L., Wolff, M.C., et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics, 108, 2001, E24, 10.1542/peds.108.2.e24.
42. [42] Navas, E., Salleras, L., Domínguez, A., Ibanez, D., Prat, A., Sentís, J., et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3–14 years from the provider and societal perspectives. Vaccine 25 (2007), 3233–3239, 10.1016/j.vaccine.2007.01.038.
43. [43] Aballéa Samuel, Martin M, Chancellor J, Carrat F, Drummond M, Weinstein M. Analyse coût-efficacité de la vaccination contre la grippe chez les personnes de 50 à 64 en France. J d’Économie Médicale 2006;24:267–85.
44. [44] Lee, P.Y., Matchar, D.B., Clements, D.A., Huber, J., Hamilton, J.D., Peterson, E.D., Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 137 (2002), 225–231, 10.1097/00019048-200205000-00027.
45. [45] Mogasale, V., Barendregt, J., Cost-effectiveness of influenza vaccination of people aged 50–64 years in Australia: results are inconclusive. Aust N Z J Public Health 35 (2011), 180–186, 10.1111/j.1753-6405.2010.00639.x.
46. [46] Neumann, P.J., Cohen, J.T., Weinstein, M.C., Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371 (2014), 796–797, 10.1056/NEJMp1405158.
47. [47] Ungar WJ. Paediatric health economic evaluations: a world view. Healthc Q 2007;10:134–40, 142-5-6.
48. [48] Munoz, F.M., The impact of influenza in children. Semin Pediatr Infect Dis 13 (2002), 72–78, 10.1053/SPID.2002.122992.
49. [49] Centre for Disease Control and Prevention. CDC Statement on LAIV Effectiveness and Vaccination of Children | News (Flu) | CDC. CDC Statement LAIV Eff Vaccin Child 2014. < https://www.cdc.gov/flu/news/nasal-spray-effectiveness.htm> [accessed January 28, 2017].
50. [50] Public Health England. Influenza vaccine effectiveness in adults and children in primary care in the UK: provisional end of season results 2015–16.
51. [51] Government of Canada Public Health Agency of Canada. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2016–2017 - Public Health Agency of Canada.
52. [52] Savidan, E., Chevat, C., Marsh, G., Economic evidence of influenza vaccination in children. Health Policy (New York) 86 (2008), 142–152, 10.1016/j.healthpol.2007.09.009.
53. [53] Newall, A.T., Jit, M., Beutels, P., Economic evaluations of childhood influenza vaccination. Pharmacoeconomics 30 (2012), 647–660, 10.2165/11599130-000000000-00000.
54. [54] Nichol, K.L., Cost-effectiveness and socio-economic aspects of childhood influenza vaccination. Vaccine 29 (2011), 7554–7558, 10.1016/j.vaccine.2011.08.015.
55. [55] Gatwood, J., Meltzer, M.I., Messonnier, M., Ortega-Sanchez, I.R., Balkrishnan, R., Prosser, L.A., Seasonal influenza vaccination of healthy working-age adults. Drugs 72 (2012), 35–48, 10.2165/11597310-000000000-00000.
56. [56] Wood, S.C., Nguyen, V.H., Schmidt, C., Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective. Pharmacoeconomics 18 (2000), 173–183.
57. [57] Postma, M.J., Baltussen, R.M., Heijnen, M.L., de Berg, L.T., Jager, J.C., Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 17 (2000), 217–227, 10.2165/00002512-200017030-00005.
58. [58] Chit, A., Lee, J.K.H., Shim, M., Nguyen, V.H., Grootendorst, P., Wu, J., et al. Economic evaluation of vaccines in Canada: a systematic review. Hum Vaccines Immunother 5515 (2016), 1–8, 10.1080/21645515.2015.1137405.
59. [59] Sander, B., Bauch, C.T., Fisman, D., Fowler, R.A., Kwong, J.C., Maetzel, A., et al. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian experience. Vaccine 28 (2010), 6210–6220, 10.1016/j.vaccine.2010.07.010.
60. [60] Fisman DN, Tuite AR. Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PLoS One 2011;6. http://dx.doi.org/10.1371/journal.pone.0027420.
61. [61] Nosyk, B., Sharif, B., Sun, H., Cooper, C., Anis, A.H., Group on behalf of the CCHTNIVR. The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus. PLoS ONE, 6, 2011, e27059, 10.1371/journal.pone.0027059.